Genvoya (emtricitabine tenofovir alafenamide cobicistat elvitegravir): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Genvoya 150mg/150mg/200mg/10mg film coated tablets

Genvoya is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:

• In adults and adolescents aged from 12 years and with body weight at least 35 kg

• In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.

See sections 4.2, 4.4 and 5.1.


Route of administration: Oral
Molecule: emtricitabine, tenofovir alafenamide, cobicistat, elvitegravir

Patients' opinions on Genvoya

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.